NY-EGON-ZEHNDER
19.11.2020 06:02:11 CET | Business Wire | Press release
Egon Zehnder, the world’s leadership advisory firm, and Out Leadership, the first and only global platform for CEOs and multinational companies to advocate for LGBTQ+ inclusion and equality, today announce a partnership aimed at promoting LGBTQ+ representation at senior levels of business.
Egon Zehnder will be the newest member of Out Leadership’s coalition, which includes such companies as P&G, Publicis Sapient, Goldman Sachs, Microsoft, Mastercard, National Australia Bank, Nomura, KPMG, Citi, Coca Cola, Dow Chemical, and LVMH. The two firms will work together on advisory and executive search services, thought leadership and events, with the goal of building a more robust pipeline for senior leadership positions and Board appointments. Per the agreement, Egon Zehnder will become a member of Out Leadership's business network and will be the exclusive search firm partner/sponsor of Quorum, Out Leadership’s brand covering all events and thought leadership initiatives related to promoting LGBT representation on corporate boards.
“At Egon Zehnder, we understand that diversity of background and thought is an imperative for business success,” says Jill Ader, Chair, Egon Zehnder. “We are thrilled to partner with Out Leadership on our joint commitment to ensure that the LGBTQ+ community is represented at the top levels of business and elsewhere in society.”
"The push for broader diversity on boards globally has too often excluded LGBTQ leaders, both in policy, placement and practice,” says Todd Sears, Founder and CEO of Out Leadership. “Out Leadership, and our Quorum initiative, have been striving since 2010 to increase LGBTQ inclusivity--especially at the board level where the greatest impact often is made. We're proud to have Egon Zehnder as our newest partner and the first of the major leadership advisory firms to recognize the importance of LGBTQ diversity both in the U.S. and around the world.”
The first joint effort between the two firms will involve the copromotion of Egon Zehnder’s Global Board Diversity Tracker, which will be released December 8th and which for the first time will involve analysis beyond gender, including research provided by Out Leadership. Ultimately the two organizations will develop proprietary research, events, and other joint projects.
About Egon Zehnder
Egon Zehnder is the world’s preeminent leadership advisory firm, sharing one goal: to help people and organizations transform. We know what great leaders can do and are passionate about delivering the best solutions for our clients. At Egon Zehnder, we passionately believe that diverse and inclusive leaders are able to create a better world where individuals and organizations not only grow; they thrive. It is central to our core values and fundamental belief that organizations deliver better performance when diverse voices are heard and individuals feel they belong. For this reason, Egon Zehnder is committed to celebrating, supporting and advocating for the LGBTQ+ community globally.
As One Firm, our more than 500 Consultants in 68 offices and 40 countries combine our individual strengths to form one powerful collaborative team. We partner closely with public and private corporations, family-owned enterprises, and non-profit and government agencies to provide a comprehensive range of integrated services: Board advisory, CEO search and succession, executive search, executive assessment, leadership development and organizational transformation.
Our leadership solutions cover individual, team and organizational effectiveness, development and cultural transformation. We work with world-class partners including Mobius Executive Leadership, a transformational leadership development firm. In addition, we have partnered with Paradox Strategies, co-founded by Harvard University Professor Linda Hill, to develop the Innovation Quotient (IQ), a proprietary culture diagnostic.
Our goal is that the work we do contributes to successful careers, stronger companies – and a better world.
For more information, visit www.egonzehnder.com and follow us on LinkedIn and Twitter .
About Out Leadership:
Out Leadership is the oldest and largest global LGBTQ+ business advisory that partners with the world’s most influential companies to build business opportunities, cultivate talent, and drive LGBTQ+ equality forward. We believe that LGBTQ+ inclusion positively impacts business results, and that including LGBTQ+ people at the most senior level of executive leadership builds business. We call this idea Return on Equality™.
Comprising 85 global member firms and dedicated to cross-industry collaboration, Out Leadership is a certified B Corporation. Out Leadership convenes CEOs, business leaders and allies at exclusive invitation only events across 4 continents. Out Leadership also operates three talent initiatives: Quorum, which aims to increase LGBTQ+ representation on corporate boards; OutNEXT, the first global talent development program for emerging LGBTQ+ leaders; and OutWOMEN, connecting senior level LGBTQ+ women in business. To learn more, please visit https://outleadership.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118006001/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 13:00:00 CEST | Press release
Partnership includes FIFA tournaments and events from 2031Agreement encompasses both physical and digital collectibles, and for the first time brings the player jersey patch program to international footballPre-match press conferences for the FIFA World Cup Final to take place at Fanatics Fest on Friday, 17 July 2026 In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football tradin
DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 11:21:00 CEST | Press release
Poster presented at ESMO Breast Cancer 2026: Exploring health policy and real-world treatment strategies for early-stage HER2-positive breast cancer across Europe. The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
